Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X:
“OrigAMI1: effect of Amivantamab in previously treated RAS wild colon cancer: encouraging outcomes in patients with a good prior response to EGFRi and longer time since prior EGFRi therapy.”
More posts featuring Akhil Santhosh.
